Effect of Cardiac Resynchronization Therapy on Left Ventricular Size and Function in Chronic Heart Failure
Top Cited Papers
Open Access
- 22 April 2003
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 107 (15) , 1985-1990
Abstract
Background— Cardiac resynchronization therapy (CRT) has recently emerged as an effective treatment for patients with moderate to severe systolic heart failure and ventricular dyssynchrony. The purpose of the present study was to determine whether improvements in left ventricular (LV) size and function were associated with CRT. Methods and Results— Doppler echocardiograms were obtained at baseline and at 3 and 6 months after therapy in 323 patients enrolled in the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) trial. Of these, 172 patients were randomized to CRT on and 151 patients to CRT off. Measurements were made of LV end-diastolic and end-systolic volumes, ejection fraction, LV mass, severity of mitral regurgitation (MR), peak transmitral velocities during early (E-wave) and late (A-wave) diastolic filling, and the myocardial performance index. At 6 months, CRT was associated with reduced end-diastolic and end-systolic volumes (both P P P P P Conclusions— CRT in patients with moderate-to-severe heart failure who were treated with optimal medical therapy is associated with reverse LV remodeling, improved systolic and diastolic function, and decreased MR. LV remodeling likely contributes to the symptomatic benefits of CRT and may herald improved longer-term survival.Keywords
This publication has 11 references indexed in Scilit:
- Cardiac Resynchronization in Chronic Heart FailureNew England Journal of Medicine, 2002
- The relationships of left ventricular ejection fraction, end-systolic volume index and infarct size to six-month mortality after hospital discharge following myocardial infarction treated by thrombolysisJACC, 2002
- Impact of cardiac resynchronization therapy using hemodynamically optimized pacing on left ventricular remodeling in patients with congestive heart failure and ventricular conduction disturbances11The PAcing THerapies in Congestive Heart Failure (PATH-CHF) study was supported by a grant from the Guidant Corporation (St. Paul, Minnesota). Drs. Pochet, Salo, Kramer and Spinelli have corporate appointments with Guidant Corp.JACC, 2001
- Left ventricular geometry and operative mortality in patients undergoing mitral valve replacementClinical Cardiology, 2001
- Effects of Multisite Biventricular Pacing in Patients with Heart Failure and Intraventricular Conduction DelayNew England Journal of Medicine, 2001
- Importance of imaging method over imaging modality in noninvasive determination of left ventricular volumes and ejection fractionJACC, 2000
- The pacing therapies for congestive heart failure (PATH-CHF) study: rationale, design, and endpoints of a prospective randomized multicenter study11For a complete list of institutions and individuals participating in the PATH-CHF Study Group, see the Appendix.The American Journal of Cardiology, 1999
- Indications for Permanent Pacing and Choice of Pacemaker1998
- Left Ventricular Dilatation and the Risk of Congestive Heart Failure in People without Myocardial InfarctionNew England Journal of Medicine, 1997
- Recommendations for Quantitation of the Left Ventricle by Two-Dimensional EchocardiographyJournal of the American Society of Echocardiography, 1989